Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide 2.4 mg Gastric Emptying in Obesity
NCT03842202Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Feb 2019
- Primary completion
- Nov 2019
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obesity comparing Semaglutide 2.4 mg with Placebo (2 arms). Primary endpoint: Area under the paracetamol concentration-time curve from 0 to 5 hours. Started Feb 2019; status: completed.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT03842202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03842202.